ADIM
RVNC

Alpha DNA Investment Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Alpha DNA Investment Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-33,552
Closed -$1.08M – 223
2023
Q1 		$1.08M Buy
+33,552
New +$1.05M 0.32% 83

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Alpha DNA Investment Management's RVNC Position: Q2 2023 in Review

Alpha DNA Investment Management sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2023, closing a stake of 33,552 shares — an estimated $1.08M sold.

Alpha DNA Investment Management first reported a position in RVNC in Q1 2023 and held it in 1 quarter. The position peaked at $1.08M in Q1 2023. 215 funds tracked by Wall St. Rank hold RVNC as of Q2 2023.

  • Alpha DNA Investment Management reported no remaining Revance Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
  • Alpha DNA Investment Management sold 33,552 Revance Therapeutics, Inc. shares in Q2 2023, an estimated $1.08M.
  • Alpha DNA Investment Management first reported a position in Revance Therapeutics, Inc. in Q1 2023 and held it in 1 quarter.
  • Alpha DNA Investment Management's Revance Therapeutics, Inc. position peaked at $1.08M in Q1 2023.
  • 215 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2023.

Based on Alpha DNA Investment Management's 13F filing for Q2 2023, filed 31 Jul 2023.